<DOC>
	<DOCNO>NCT00427700</DOCNO>
	<brief_summary>The Polycystic Ovarian Syndrome ( PCOS ) common disorder related ovulation problem . Clomiphene citrate ( CC ) drug first choice condition . Nevertheless , CC detrimental effect uterine receptivity . Raloxifene Selective Estrogen Receptor Modulator , detrimental effect endometrium , also increase serum level FSH , thus , induct ovulation . The objective study compare ovulation rate PCOS patient clomiphene citrate raloxifene double blind randomize trial .</brief_summary>
	<brief_title>Induction Ovulation With Raloxifene Clomiphene Citrate Polycystic Ovarian Syndrome</brief_title>
	<detailed_description>-Introduction The Polycystic Ovarian Syndrome ( PCOS ) frequent endocrine among woman reproductive age , prevalence 10 % . In 2003 , consensus among European American Society Human Reproduction ( ESRHE ASRM ) define PCOS ovarian disfunction present least 2 3 criterion : oligomenorrhea anovulation ; clinical laboratorial sign hyperandrogenism polycystic ovary ultrasound ; cause , congenital adrenal hyperplasia , androgen secretory tumor , Cushing syndrome hyperprolactinemia must rule . Patients PCOS desire become pregnant need , majority , induction ovulation . Traditionally , clomiphene citrate , estrogen receptor agonist , use drug type anovulation . The mechanism action clomiphene relate negative feedback endogenous estrogen , result high amplitude gonadotrophin surge , i.e. , luteinizing hormone ( LH ) follicle stimulate hormone ( FSH ) . Nevertheless , recent study show clomiphene citrate deleterious effect endometrium . The marker uterine receptivity , among , integrin beta3 subunit , expression diminish , implicate reduce fecundation rate . The raloxifene selective estrogen receptor modulator . It agonist antagonist activity different organ . The daily therapy raloxifene increase bone density , reduce cholesterol serum concentration ( LDL ) stimulate endometrium post-menopausal woman ( Delmas PD et al. , 1997 ) . Recent study show drug safe healthy pre-menopausal woman ( Baker VL et al. , 1998 ) . A daily dosi 100mg per 28 day , begin 3rd day cycle , show FSH LH level affect compare control menstrual cycle . However , woman receive 100mg raloxifene 31 % increase FSH serum level follicular phase , compare control . An increase 200mg increase FSH level ( Baker VL et al , 1998 ) . Furthermore , show raloxifene significantly increase vitro expression αvβ3 integrin , suggest beneficial effect endometrium relation clomiphene ( Lessey BA , personal communication , 2006 ) . -Objective To compare ovulation rate raloxifene clomiphene among woman polycystic ovarian syndrome . To identify endometrial alteration compatible ovulation , i.e. , secretory endometrium , endometrial biopsy woman use raloxifene clomiphene . -Patients Methods Patients diagnosis polycystic ovarian syndrome ( infertility hirsutism ) consultation outpatient clinic Hospital de Clínicas de Porto Alegre invite participate study , sign informed consent . A standard interview perform . In first consultation , laboratorial exam review : total testosterone , 17 OH-progesterone , fast glucose , TSH , prolactin . After interview , patient randomize one treatment : 100mg clomiphene 100mg raloxifene day 3 menstrual cycle , 5 day . Menstruation induce 10mg oral medroxyprogesterone per 10 day . On day 10 , urinary LH collect daily along endovaginal ultrasound assess follicular development . On post-ovulatory day 8~10 , progesterone level measure blood . An endometrial biopsy day 8~10 post-ovulation perform patient wish become pregnant . The endometrial biopsy divide 2 part keep liquid nitrogen formol immunohistochemistry histological analysis respectively . Sample size statistical analysis Ethical aspect</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Polycystic Ovary Syndrome</mesh_term>
	<mesh_term>Clomiphene</mesh_term>
	<mesh_term>Enclomiphene</mesh_term>
	<mesh_term>Zuclomiphene</mesh_term>
	<mesh_term>Raloxifene Hydrochloride</mesh_term>
	<mesh_term>Citric Acid</mesh_term>
	<criteria>All patient polycystic ovarian syndrome invite participate study . The PCOS criterion accord modify Rotterdam criterion ( 7 ) ; i.e. , oligoovulation define &lt; 6 menstrual period per year , sign clinical hyperandrogenism ( Ferriman Gallwey &gt; 8 ) laboratorial ( total Testosterone &gt; =0.81 ng/dL ) polycystic ovary &gt; 10cm3 . Furthermore , patient infertility diagnosis base solely ovulation factor include protocol Age &gt; 18 year old &lt; = 38 year old . No endometriosis laparoscopy Not willing participate study use IUD contraceptive pill within 2 month study . Hyperprolactinemia ( &gt; 20ng/mL ) Abnormal serum level TSH ( normal range:0.440 mUI/mL ) . High 17OH progesterone ( &gt; =4.9ng/mL ) Endometriosis Known allergy clomiphene raloxifene</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>38 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Polycystic Ovary Syndrome</keyword>
	<keyword>clomiphene citrate</keyword>
	<keyword>Raloxifene</keyword>
</DOC>